kawasaki
diseas
kd
acut
selflimit
vascul
present
characterist
clinic
featur
first
describ
high
preval
coronari
arteri
aneurysmectasia
associ
cardiovascular
morbid
untreat
children
well
character
kawasaki
diseas
lead
caus
pediatr
acquir
heart
diseas
usa
prompt
treatment
highdos
intraven
immun
globulin
ivig
reduc
incid
coronari
arteri
abnorm
howev
signific
gap
remain
understand
kd
underli
etiolog
remain
unknown
epidemiolog
studi
recent
attribut
possibl
sourc
etiolog
agent
kd
northern
china
subsequ
spread
japan
via
tropospher
wind
diagnosi
kd
remain
primarili
base
upon
characterist
clinic
featur
day
fever
bilater
nonpurul
conjunct
rash
cervic
lymphadenopathi
mucocutan
chang
howev
diagnost
challeng
often
aris
given
signific
overlap
clinic
featur
kd
pediatr
ill
addit
kd
also
present
incomplet
clinic
featur
number
atyp
present
yet
accur
diagnosi
integr
prevent
morbid
mortal
kd
prompt
treatment
ivig
significantli
reduc
incid
longterm
cardiac
complic
recent
epidemiolog
data
describ
diverg
incid
kd
west
north
america
australia
europ
east
asia
japan
taiwan
korea
west
current
incid
kd
children
year
last
decad
overal
incid
west
plateau
follow
initi
increas
comparison
incid
kd
east
asian
countri
continu
increas
current
report
incid
time
higher
usa
europ
japan
highest
incid
kd
children
year
countri
follow
korea
taiwan
ethnic
variat
incid
kd
suggest
genet
suscept
signific
factor
higher
preval
kd
east
asian
countri
within
usa
incid
kd
rang
children
year
howev
incid
kd
significantli
higher
pacif
island
african
american
particular
american
japanes
ancestri
hawaii
exhibit
similar
incid
kd
gener
popul
japan
children
year
mani
infecti
etiolog
kd
propos
although
put
agent
isol
young
age
children
affect
kd
suggest
kd
trigger
agent
popul
becom
immun
late
childhood
varieti
bacteri
viral
pathogen
isol
patient
kd
includ
staphylococcu
aureu
streptococcu
pyogen
adenoviru
parvoviru
human
herp
viru
rotaviru
human
coronaviru
bocaviru
parainfluenza
epsteinbarr
dengu
varicellazost
measl
influenza
virus
intracytoplasm
inclus
bodi
found
bronchial
epithelium
autopsi
may
support
viral
etiolog
etiolog
import
concurr
infecti
pathogen
seem
limit
possibl
superantigenbacteri
toxin
etiolog
postul
due
similar
desquam
found
scarlet
fever
toxic
shock
syndrom
kd
howev
signific
support
data
lack
paralysi
adapt
immun
system
typic
seen
superantigenmedi
ill
seen
kd
addit
bacteri
toxin
detect
peripher
blood
kd
patient
make
toxin
unlik
respons
diffus
inflamm
found
acut
kd
primari
autoimmun
etiolog
unlik
due
selflimit
nonrecur
natur
kd
correl
season
kd
tropospher
wind
dens
cultiv
region
northeastern
china
japan
suggest
possibl
windborn
pathogen
underli
etiolog
kd
nevertheless
clinic
featur
kd
may
result
common
pathway
immunemedi
vascular
inflamm
varieti
incit
infect
rather
infect
specif
pathogen
fact
put
infecti
agent
isol
despit
signific
investig
support
hypothesi
exposur
caus
trigger
system
inflamm
induc
host
incomplet
understood
cascad
inflamm
primarili
target
mediums
muscular
arteri
notabl
coronari
arteri
initi
infiltr
primarili
neutrophil
first
week
follow
infiltr
eosinophil
cell
week
diseas
onset
investig
coronari
arteri
light
transmiss
electron
microscopi
identifi
three
distinct
vascular
process
necrot
arter
na
subacutechron
sac
vascul
lumin
myofibroblast
prolifer
extent
perman
vascular
damag
depend
upon
scope
involv
vascular
inflamm
mild
inflamm
damag
gener
preserv
intern
extern
elast
lamina
may
caus
mild
dilat
allow
arteri
maintain
normal
morpholog
sever
inflamm
increas
intern
extern
elast
lamina
destroy
result
progress
larger
aneurysm
aneurysm
may
fusiform
mild
sac
vascul
saccular
sever
sac
vascul
na
aneurysm
risk
ruptur
develop
thrombosi
thrombosi
may
result
ischemiamyocardi
infarct
undergo
organ
ultim
recan
coronari
arteri
aneurysm
also
previous
describ
remodel
regress
singl
diagnost
test
pathognomon
clinic
featur
kd
therefor
thorough
histori
physic
examin
establish
clinic
diagnost
criteria
essenti
classic
clinic
criteria
diagnosi
kd
requir
presenc
day
fever
clinic
featur
see
tabl
characterist
clinic
featur
typic
present
time
therefor
continu
close
observ
may
necessari
make
diagnosi
fever
kd
highspik
peak
mean
durat
day
although
report
last
week
absenc
treatment
upon
initi
treatment
fever
typic
resolv
within
day
extrem
chang
initi
present
erythema
indur
swell
hand
andor
feet
acut
phase
kd
desquam
finger
toe
typic
late
find
begin
week
onset
fever
polymorph
exanthema
kd
may
take
variou
form
maculopapular
rash
common
scarlatiniform
rash
erythroderma
erythemamultiform
micropustular
bullousvesicular
rash
describ
rash
typic
present
within
first
day
fever
gener
erupt
involv
trunk
extrem
perin
region
earli
desquam
may
occur
region
perineum
strong
indic
kd
bilater
conjunctiv
inject
kd
affect
bulbar
conjunctiva
spare
limbu
inject
nonpurul
painless
present
shortli
onset
fever
mild
anterior
uveiti
may
present
slit
lamp
examin
oral
caviti
lip
chang
kd
present
includ
gener
erythema
lip
oropharyng
mucosa
peelingcrackingfissur
lip
erythema
promin
fungiform
papilla
tongu
commonli
refer
strawberri
tongu
strawberri
tongu
uniqu
kd
also
associ
streptococc
scarlet
fever
cervic
lymphadenopathi
kd
usual
unilater
classic
present
anterior
cervic
triangl
diagnost
criteria
requir
enlarg
lymph
node
cm
diamet
classic
clinic
featur
cervic
lymphadenopathi
least
commonli
observ
diagnosi
incomplet
kd
made
patient
fulfil
classic
clinic
criteria
see
fig
incomplet
kd
separ
entiti
atyp
kd
present
symptom
typic
seen
kd
incomplet
kd
consid
children
unexplain
fever
day
addit
presenc
princip
clinic
featur
kd
higher
preval
incomplet
present
younger
children
therefor
incomplet
kd
consid
young
children
month
old
unexplain
fever
day
associ
clinic
featur
kd
evalu
incomplet
kd
presenc
support
laboratori
echocardiogram
find
see
tabl
use
ultim
confirm
diagnosi
term
atyp
kd
use
interchang
incomplet
kd
past
reserv
case
kd
present
find
rare
associ
kd
featur
includ
transient
unilater
peripher
facial
nerv
palsi
transient
highfrequ
sensorineur
hear
loss
hepat
enlarg
jaundic
acalcul
gallbladd
distent
testicular
swell
pulmonari
nodul
pleural
effus
hemophagocyt
syndrom
also
report
less
common
kawasaki
shock
syndrom
present
kd
diseas
systol
hypotens
clinic
sign
poor
perfus
also
describ
rare
present
kd
major
cardiac
sequela
kd
affect
coronari
arteri
system
pericardium
myocardium
endocardium
valv
coronari
arteri
may
affect
diffus
inflammatori
process
kd
may
present
pericard
myocard
valvul
new
valvular
regurgit
gallop
rhythm
innoc
flow
murmur
may
also
present
commonli
set
anemia
fever
acut
kd
poor
myocardi
function
also
result
cardiogen
shock
arrhythmia
prolong
pr
interv
nonspecif
st
wave
chang
may
present
ekg
supplementari
laboratori
criteria
support
diagnosi
kd
list
tabl
includ
hypoalbuminemia
anemia
age
elev
alanin
aminotransferas
alt
thrombocytosi
day
leukocytosi
steril
pyuria
addit
nonspecif
laboratori
find
elev
marker
inflamm
erythrocyt
sediment
rate
esr
creactiv
protein
crp
approxim
patient
kd
wbc
anemia
may
develop
patient
prolong
durat
activ
inflamm
typic
present
normal
rbc
index
acut
phase
reactant
elev
esrcrp
nearli
univers
present
although
discord
esrcrp
seen
acut
present
kd
thrombocytosi
platelet
count
millionmm
late
featur
kd
commonli
occur
second
week
diseas
slowli
resolv
week
uncompl
kd
elev
alt
typic
mild
moder
occur
case
hypoalbuminemia
albumin
associ
sever
prolong
diseas
steril
pyuria
present
approxim
one
third
patient
steril
pyuria
found
suprapub
aspir
urin
underli
urethr
present
kd
differenti
diagnosi
patient
present
clinic
featur
kd
vast
consider
overlap
clinic
featur
kd
sever
common
pediatr
ill
includ
limit
adenoviru
infect
bacteri
cervic
aden
retropharyng
abscess
system
onset
jra
toxic
shock
syndrom
incomplet
kd
often
present
greatest
diagnost
challeng
initi
present
may
consist
previous
mention
clinic
ill
given
limit
clinic
manifest
therefor
essenti
consid
kd
differenti
diagnosi
ill
adenoviru
infect
one
common
pediatr
infect
compris
pediatr
respiratori
ill
presenc
adenoviru
detect
polymeras
chain
reaction
pcr
test
nasopharynx
np
swab
healthi
children
patient
kd
subsequ
develop
coronari
arteri
abnorm
incident
detect
adenoviru
pcr
np
swab
describ
therefor
accur
differenti
incident
detect
adenoviru
patient
kd
primari
adenovir
diseas
essenti
avoid
subsequ
mortalitymorbid
associ
undiagnos
kd
prolong
fever
elev
inflammatori
marker
common
featur
adenoviru
infect
kd
commonli
describ
clinic
featur
kd
compar
adenovir
infect
report
cohort
studi
conjunct
featur
adenoviru
conjunct
includ
unilater
onset
promin
tear
frequent
purul
follicular
hyperplasia
addit
adenoviru
often
present
pharyngoconjunctiv
fever
character
nonexud
exud
pharyng
addit
conjunct
extrem
chang
unilater
neck
swell
least
common
clinic
featur
kd
seen
patient
adenovir
diseas
nodefirst
present
kd
nfkd
manifest
kd
fever
cervic
adenopathi
prior
present
clinic
featur
kd
compar
typic
kd
patient
nfkd
tend
older
higher
marker
inflamm
nodefirst
present
kd
may
often
misdiagnos
bacteri
cervic
aden
fever
cervic
adenopathi
characterist
clinic
find
diseas
laboratori
find
aid
differenti
two
entiti
includ
lower
wbc
count
hemoglobin
platelet
count
higher
absolut
band
count
crp
esr
alt
nfkd
addit
radiograph
find
bacteri
cervic
aden
favor
singl
domin
node
conglomer
suppur
lymph
node
convers
radiograph
find
nfkd
favor
multipl
discret
node
retropharyng
edema
rare
present
kd
due
unfamiliar
present
often
misdiagnos
retropharyng
abscess
mani
patient
underw
pharyng
needl
aspir
antibiot
therapi
due
misdiagnosi
delay
treatment
kd
increas
risk
develop
coronari
arteri
abnorm
diagnosi
kd
retropharyng
edema
consid
patient
diagnos
retropharyng
abscess
subsequ
found
steril
cultur
result
surgic
drainag
signific
differ
laboratori
find
two
entiti
clinic
symptom
classic
associ
retropharyng
abscess
stridor
neck
pain
dysphagia
less
common
retropharyng
edema
kd
radiolog
find
ring
enhanc
mass
effect
neck
ct
commonli
found
patient
retropharyng
abscess
system
onset
juvenil
idiopath
arthriti
sojia
autoimmun
diseas
character
sever
inflamm
multipl
organ
system
clinic
featur
earli
stage
sojia
fever
rash
thrombocytosi
increas
marker
inflamm
arthriti
may
resembl
kd
coronari
arteri
dilat
present
sojia
less
common
arthriti
featur
may
present
kd
sojia
gener
mild
selflimit
kd
compar
persist
sever
arthriti
sojia
often
requir
treatment
immunosuppress
agent
resolut
rash
sojia
typic
intermitt
coincid
fever
spike
compar
fix
rash
kd
presenc
mucocutan
find
suggest
kd
find
absent
sojia
addit
thrombocytosi
typic
late
find
kd
occur
second
week
diseas
compar
earli
stage
sojia
ivig
adjunct
rather
primari
modal
therapi
sojia
diagnosi
sojia
consid
patient
kd
respond
multipl
ivig
infus
toxic
shock
syndrom
tss
toxinmedi
diseas
present
clinic
featur
fever
hypotens
rash
subsequ
desquam
skin
multiorgan
involv
may
confus
kd
common
caus
organ
aureu
condit
misdiagnos
kd
due
similar
clinic
featur
rash
fever
hypotens
tss
misattribut
shock
associ
kd
patient
present
tss
averag
older
mean
age
month
patient
kd
month
featur
suggest
tss
includ
elev
creatinin
labil
blood
pressur
requir
higher
vasopressor
support
increas
fluid
resuscit
featur
suggest
kd
includ
anemia
thrombocytosi
cardiac
abnorm
use
intraven
immun
globulin
ivig
acut
phase
kd
prevent
develop
coronari
arteri
abnorm
well
defin
treatment
ivig
within
first
day
ill
reduc
risk
develop
coronari
arteri
abnorm
approxim
mechan
action
remain
unknown
gener
antiinflammatori
effect
ivig
like
inhibit
progress
kd
ultim
prevent
develop
coronari
arteri
abnorm
use
ivig
recommend
treatment
patient
kd
shown
cost
effect
dose
gmkg
singl
infus
ivig
given
initi
treatment
kd
treatment
institut
within
first
day
ill
still
administ
children
tenth
day
ill
fever
persist
ongo
system
inflamm
elev
esrcrp
presenc
coronari
arteri
abnorm
treatment
kd
prior
day
ill
may
associ
increas
need
ivig
retreat
live
vaccin
particularli
measl
varicella
defer
month
ivig
treatment
children
high
risk
measl
exposur
may
vaccin
earlier
requir
reimmun
month
ivig
treatment
treatment
ivig
given
concurr
aspirin
see
acut
phase
kd
aspirin
asa
administ
high
dosag
mgkgday
divid
everi
h
concurr
administr
highdos
asa
ivig
acut
phase
kd
seem
provid
addit
antiinflammatori
effect
highdos
aspirin
alon
lower
frequenc
develop
coronari
abnorm
despit
antiinflammatori
effect
durat
highdos
aspirin
therapi
vari
institut
institut
requir
resolut
fever
h
prior
stop
highdos
asa
therapi
howev
institut
treat
highdos
asa
day
ill
regardless
fever
resolut
highdos
asa
discontinu
lowdos
asa
mgkg
given
daili
start
lowdos
asa
use
antiplatelet
effect
prevent
possibl
complic
coronari
arteri
abnorm
associ
kd
evalu
coronari
abnorm
done
least
week
onset
kd
lowdos
asa
discontinu
evid
coronari
abnorm
platelet
count
normal
time
evid
coronari
abnorm
develop
persist
lowdos
asa
continu
indefinit
ibuprofen
avoid
patient
asa
antagon
platelet
inhibit
asa
children
receiv
asa
therapi
risk
develop
rey
syndrom
particularli
activ
infect
varicella
influenza
rey
syndrom
report
patient
receiv
prolong
highdos
asa
therapi
kd
although
unclear
whether
lowdos
asa
increas
risk
rey
syndrom
children
longterm
asa
therapi
receiv
inactiv
influenza
vaccin
physician
evalu
patient
asa
expos
develop
symptom
influenza
varicella
approxim
patient
kd
fail
respond
initi
treatment
ivig
failur
respond
character
persist
fever
h
follow
complet
ivig
infus
like
explan
persist
fever
patient
failur
initi
ivig
abort
diseas
process
kd
howev
kd
misdiagnos
due
share
clinic
characterist
wide
varieti
common
pediatr
ill
therefor
patient
refractori
kd
assess
possibl
misdiagnosi
kd
well
see
diagnost
challeng
section
patient
kd
fail
respond
initi
ivig
therapi
receiv
repeat
infus
ivig
dose
gmkg
singl
infus
retreat
lower
dose
gmkg
associ
increas
risk
develop
coronari
abnorm
puls
steroid
therapi
patient
kd
refractori
two
ivig
infus
gmkg
infus
follow
gmkg
infus
associ
shorter
durat
fever
hospit
stay
compar
repeat
gmkg
ivig
infus
use
corticosteroid
patient
kd
current
reserv
children
receiv
infus
ivig
basi
effect
steroid
therapi
coronari
arteri
abnorm
uncertain
time
public
kd
treatment
guidelin
commonli
use
steroid
regimen
iv
methylprednisolon
ivmp
mgkg
daili
day
research
use
corticosteroid
primari
treatment
kd
remain
ongo
random
control
trial
newburg
et
al
show
addit
one
dose
ivmp
therapi
initi
ivig
infus
reduc
preval
coronari
arteri
abnorm
total
length
hospit
stay
japan
studi
efficaci
ivig
steroid
patient
sever
present
kd
rais
studi
multicent
prospect
random
openlabel
blindedendpoint
trial
show
combin
treatment
ivig
prednisolon
signific
advantag
ivig
alon
prevent
coronari
arteri
abnorm
rapid
defervesc
fever
normal
inflammatori
marker
sever
kd
determin
risk
score
evalu
five
point
higher
per
kobayashi
risk
score
scale
predict
probabl
nonrespons
initi
ivig
treatment
tabl
signific
differ
corticosteroid
regimen
two
trial
median
start
time
therapi
rais
studi
day
earlier
trial
newburg
et
al
addit
steroid
dosag
rais
studi
iv
prednison
mgkg
divid
three
time
day
day
follow
titrat
oral
prednisolon
dose
mgkgday
resolut
fever
improv
inflammatori
marker
median
durat
steroid
therapi
rais
studi
day
signific
increas
total
steroid
dose
compar
singl
dose
mgkg
methylprednisolon
newburg
studi
earlier
initi
ivig
corticosteroid
therapi
subsequ
increas
steroid
treatment
durat
associ
significantli
lower
rate
coronari
arteri
abnorm
rais
studi
may
result
earli
suppress
vascul
preced
vascular
remodel
due
earli
initi
corticosteroid
therapi
addit
corticosteroid
therapi
initi
treatment
regimen
kd
standard
care
time
infliximab
remicaid
human
monoclon
antibodi
tumor
necrosi
factor
tnf
use
treatment
refractori
kawasaki
diseas
acut
phase
kd
markedli
elev
degre
elev
correl
develop
coronari
arteri
abnorm
commonli
use
regimen
one
infliximab
infus
dose
mgkg
two
retrospect
review
patient
refractori
kd
treat
infliximab
show
complet
resolut
symptom
major
patient
refractori
kd
follow
administr
infliximab
addit
recent
pilot
studi
random
patient
kd
refractori
initi
ivig
infus
receiv
either
repeat
ivig
gmkg
infliximab
mgkg
treatment
infliximab
associ
shorten
durat
fever
length
hospit
possibl
reduct
need
retreat
effect
infliximab
develop
coronari
arteri
abnorm
kd
remain
unclear
studi
show
reduct
develop
coronari
arteri
abnorm
howev
regress
progress
coronari
arteri
dilationform
resolut
dilat
coronari
arteri
follow
infliximab
infus
report
therefor
infliximab
may
inhibit
progress
coronari
arteri
dilat
injuri
rather
prevent
format
coronari
arteri
abnorm
phase
random
doubleblind
placebocontrol
trial
addit
infliximab
reduc
treatment
resist
initi
therapi
shorten
fever
durat
time
normal
inflammatori
marker
crp
esr
larger
decreas
z
score
left
anterior
descend
coronari
arteri
current
indic
addit
infliximab
initi
treatment
regimen
uncompl
kd
cyclosporin
csa
calcineurin
inhibitor
target
ca
nfat
signal
pathway
pathway
associ
immun
hyperreact
unrespons
ivig
therapi
coronari
arteri
abnorm
kd
patient
associ
singl
nucleotid
polymorph
gene
itpkc
downregul
ca
nfat
signal
pathway
therefor
inhibit
ca
ca
nfat
signal
pathway
csa
may
consid
patient
refractori
kd
retrospect
review
patient
refractori
kd
treat
csa
dose
mgkgday
day
patient
becam
afebril
within
day
patient
significantli
lower
serum
inflammatori
cytokin
found
phase
iii
multicent
random
openlabel
blindedend
point
trial
evalu
efficaci
safeti
immunoglobulin
plu
cyclosporin
patient
sever
kd
kaica
trial
current
ongo
japan
trial
aim
compar
ivig
concurr
csa
therapi
ivig
therapi
alon
patient
sever
kd
defin
kobayashi
risk
score
scale
primari
endpoint
frequenc
coronari
arteri
abnorm
week
follow
dose
csa
kaica
trial
mgkgday
target
blood
concentr
level
ngml
total
day
prevent
thrombosi
patient
kd
vari
extent
coronari
arteri
abnorm
present
patient
lowdos
asa
appropri
asymptomat
patient
mild
stabl
diseas
howev
sever
coronari
arteri
enlarg
increas
combin
asa
antiplatelet
agent
clopidogrel
warrant
addit
anticoagul
necessari
coronari
aneurysm
expans
frequent
warfarin
ad
lowdos
aspirin
patient
giant
aneurysm
low
molecular
weight
heparin
also
use
place
warfarin
physician
efficaci
antiinflammatori
agent
treatment
kd
current
investig
particular
interest
efficaci
new
agent
kd
complic
coronari
arteri
abnorm
current
treatment
regimen
ivig
aspirin
well
document
reduc
incid
coronari
arteri
abnorm
kd
effect
agent
prevent
progress
coronari
arteri
abnorm
current
investig
inflammatori
pathway
upregul
kd
involv
coronari
arteri
inflamm
blockad
pathway
mous
model
kd
shown
prevent
develop
coronari
arteri
abnorm
anakinra
receptor
antagonist
use
rare
case
refractori
kd
anakid
trial
phase
iiia
trial
anakinra
kd
patient
coronari
arteri
abnorm
ongo
usa
subject
receiv
cours
daili
anakinra
inject
studi
aim
evalu
safeti
toler
anakinra
preventattenu
coronari
arteri
damag
patient
kd
kawakinra
trial
phase
iia
multicent
trial
anakinra
kd
patient
fail
respond
initi
ivig
therapi
persist
fever
h
infus
current
enrol
europ
clinicaltrialsgov
addit
welldocu
cholesterol
lower
effect
statin
like
antiinflammatori
antioxid
effect
statin
associ
reduct
inflammatori
marker
crp
cholesterol
recurr
event
care
trial
found
higher
risk
recurr
myocardi
infarct
patient
normal
cholesterol
level
receiv
placebo
rather
pravastatin
antiinflammatori
antioxid
endotheli
heal
properti
statin
postul
benefici
block
progress
coronari
arteri
abnorm
kd
use
pravastatin
patient
histori
kd
giant
left
coronari
arteri
aneurysm
shown
reduct
coronari
arteri
inflamm
addit
treatment
children
kd
complic
medium
giant
coronari
arteri
aneurysm
pravastatin
result
improv
endotheli
function
measur
flowmedi
dilat
reduct
crp
current
phase
iiia
dose
escal
studi
atorvastatin
determin
safeti
pharamacokinet
activ
children
acut
kd
coronari
arteri
abnorm
clinicaltrialsgov
diagnosi
initi
treatment
kd
ivig
aspirin
remain
unchang
american
heart
associ
aha
treatment
guidelin
howev
diagnost
challeng
exist
particularli
present
incomplet
kd
due
overlap
clinic
featur
kd
common
pediatr
ill
prompt
treatment
ivig
aspirin
remain
mainstay
treatment
treatment
option
human
anim
right
inform
consent
articl
contain
studi
human
anim
subject
perform
author
